Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction (CLARITY-TIMI28)
A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy
Sponsor: Bristol-Myers Squibb
A PHASE3 clinical study on Acute Coronary Syndromes, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 8 data snapshots since 2003. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
8 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Berlin, Germany , Bridgewater, United States , Bromma, Sweden , Budapest, Hungary , Buenos Aires, Argentina , Diegem, Belgium , Dublin, Ireland , Gouda, Netherlands , Guildford, United Kingdom and 14 more locations